Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma

ConclusionWe provide the data showing that PEG-LD 50  mg/m2 combined with cisplatin 100  mg/m2 demonstrated an acceptable safety profile and promising clinical activity in advanced osteosarcoma, which merits further evaluation in phase II studies.Trial registrationChiCTR1900021550.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research